Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives $18.50 Consensus PT from Brokerages

Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $18.50.

A number of analysts have recently issued reports on the stock. Guggenheim upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 11th. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research note on Wednesday, February 18th. Oppenheimer started coverage on shares of Entrada Therapeutics in a research note on Wednesday, January 28th. They set an “outperform” rating and a $21.00 price target on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Entrada Therapeutics in a report on Friday, March 27th. Finally, Wall Street Zen cut shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th.

Insider Buying and Selling at Entrada Therapeutics

In related news, COO Nathan J. Dowden sold 11,894 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $13.05, for a total transaction of $155,216.70. Following the sale, the chief operating officer directly owned 198,588 shares of the company’s stock, valued at approximately $2,591,573.40. This represents a 5.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Kory James Wentworth sold 11,388 shares of the firm’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $13.02, for a total value of $148,271.76. Following the transaction, the chief financial officer owned 121,510 shares in the company, valued at $1,582,060.20. This trade represents a 8.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 41,975 shares of company stock valued at $540,444. 8.11% of the stock is owned by company insiders.

Institutional Investors Weigh In On Entrada Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC boosted its holdings in shares of Entrada Therapeutics by 9.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock valued at $176,000 after acquiring an additional 1,560 shares during the period. Alliancebernstein L.P. increased its stake in shares of Entrada Therapeutics by 7.1% in the third quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock valued at $141,000 after purchasing an additional 1,620 shares during the period. Great Lakes Advisors LLC increased its stake in shares of Entrada Therapeutics by 5.5% in the fourth quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock valued at $445,000 after purchasing an additional 2,239 shares during the period. Intech Investment Management LLC raised its holdings in shares of Entrada Therapeutics by 15.7% during the second quarter. Intech Investment Management LLC now owns 17,702 shares of the company’s stock valued at $119,000 after buying an additional 2,397 shares during the last quarter. Finally, Quadrature Capital Ltd raised its holdings in shares of Entrada Therapeutics by 13.5% during the fourth quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock valued at $209,000 after buying an additional 2,424 shares during the last quarter. Institutional investors and hedge funds own 86.39% of the company’s stock.

Entrada Therapeutics Price Performance

Shares of TRDA opened at $13.15 on Wednesday. Entrada Therapeutics has a 12 month low of $4.93 and a 12 month high of $13.66. The stock’s 50-day moving average is $11.80 and its two-hundred day moving average is $9.72. The stock has a market cap of $503.38 million, a PE ratio of -3.80 and a beta of -0.15.

Entrada Therapeutics (NASDAQ:TRDA) last posted its earnings results on Thursday, February 26th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.38. The business had revenue of $1.30 million during the quarter, compared to analyst estimates of $7.41 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%. On average, research analysts anticipate that Entrada Therapeutics will post 1.12 earnings per share for the current year.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.